Top Markets
#1 Velas Velas +562.78%
#2 Polymath Polymath +529.94%
#3 Galxe Galxe +96.05%
#4 XION XION +63.34%
#5 Resolv wstUSR Resolv wstUSR +59.11%
#6 Nomina Nomina +45.78%
#7 Cofinex Cofinex +26.87%
#8 Swarms Swarms +16.74%
#9 Unibase Unibase +15.72%
#10 Cysic Cysic +14.51%
Coin of the day
Velas Velas
Settings
Language
ENGLISH
Currency
USD
Theme
Exscientia plc Exscientia plc

Exscientia plc

EXAI
Rank in Stocks #99999
Exscientia plc, an artificial intelligence-driven pharmatech company, engages... Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Share Price
$4.84
Market Cap
$633.18M
Change (1 day)
3.20%
Change (1 year)
0.00%
Country
GB
Trade Exscientia plc (EXAI)

Category

Healthcare
P/E ratio for Exscientia plc (EXAI)
P/E ratio as of April 2026 TTM: -3.11
According to Exscientia plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.11. At the end of 2022 the company had a P/E ratio of -5.58.
P/E ratio history for Exscientia plc from 2019 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -3.11 -27.60%
2023 -4.29 -23.09%
2022 -5.58 -88.46%
2021 -48.32 -38.55%
2020 -78.63 -73.53%
2019 -297.02 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 10.02 -422.49%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.68 -1,023.36%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 17.65 -668.21%
US
UCB SA UCB SA
UCB SA
UCB.BR
 31.52 -1,114.94%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 33.03 -1,163.31%
AU
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.